Last edition
News about "MagnetisMM-5 Phase 3 trial"
Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma
Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).
MagnetisMM-5 Phase 3 Trial | 01/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members